An interventional study of nNO testing in Primary Ciliary Dyskinesia, sponsored by Vanderbilt University Medical Center. Recruiting at 1 site in United States. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by Vanderbilt University Medical Center · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Ciliary Motility Disorders with a site in United States — 9 open to participants now, 11 under way, none of them phase 3. Ciliary Motility Disorders · United States.
Among the 28 studies in Ciliary Motility Disorders with a site in United States, this one is the only one that started in 2017, is one of 5 with no phase, and was the 12th registered.
80 studies on the registry are indexed under Ciliary Motility Disorders; 27 are open to participants now.
Browse Ciliary Motility Disorders studies →9 of the 28 studies in Ciliary Motility Disorders with a site in United States are open now. Recruiting first, the newest first:
Indiana University · Sites in United States
Ages 8–70 · Healthy volunteers
Connecticut Children's Medical Center · Sites in United States
Ages 2+
Indiana University · Sites in United States
Ages 6+ · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 2–99
The University of Texas Health Science Center, Houston · Sites in United States
Ages 4–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 21 Ciliary Motility Disorders studies recruiting now, 15 (71%) set no upper age limit and 3 (14%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.
This study: 1 Year and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 32 across 24 interventional studies indexed under Ciliary Motility Disorders.
Median enrollment 27 across the 9 interventional studies, 150 across the 19 observational. Of the 17 that completed or were terminated, 2 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 28 have an industry lead sponsor. The 10 most frequent:
Vanderbilt University Medical Center is the lead sponsor of 837 studies on the registry; 157 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 92 (73%) have results posted.
Vanderbilt University Medical Center has 2 studies filed under Ciliary Motility Disorders — fewer than ten, so there is no comparison to draw.
3 of the studies in Ciliary Motility Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03256773University of Alabama at BirminghamHigh Resolution Micro OCT Imaging | 2026-12-31 |
| NCT07699302University of North Carolina, Chapel HillClearance in Primary Ciliary Dyskinesia | 2027-01 |
| NCT00807482University of North Carolina, Chapel HillPathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies in Ciliary Motility Disorders with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a study evaluating the utility of current Primary Ciliary Dyskinesia (PCD) diagnostic tests, including nasal nitric oxide testing.
This study is a prospective data collection of individuals referred to the investigators clinical center for considerations of PCD. Participants sign informed consent to have clinical information entered into a secure electronic database. As part of this study, participants may have nasal nitric oxide (nNO) testing performed. nNO testing is a research procedure, but it is a test with growing utility for making a diagnosis of PCD when performed in the right clinical setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will have nNO testing is indicated. All participants in this study have some basic clinical data collected at time of enrollment. Participants with a confirmed diagnosis of PCD or in those participants with a working diagnosis of PCD in which ongoing nNO testing is performed have prospective data collection. Some participants have a confirmed diagnosis of PCD by genetics or ciliary biopsy at time of study entry and thus do not need nNO testing, but are followed prospectively with collection of basic clinical data
Other: nNO testing
Collection of already performed clinical data and nNO testing
frequency of nNO tests performed
number of tests
Time frame: 3 years
Frequency of genetic tests performed
number of tests
Time frame: 3 years
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2017 (actual). Primary completion is estimated for Jun 2028, 132 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vanderbilt University Medical Center →